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Physiology of endothelin in producing
myocardial perfusion heterogeneity:
A mechanistic study using darusentan
and positron emission tomography
Nils P. Johnson, MD, MS and K. Lance Gould, MD
Background. Heterogeneity of resting perfusion may be due in part to up-regulation of
coronary vasoconstriction via endothelin (ET) type A receptors, as homogeneity increases
during subsequent vasodilatory hyperemia. Therefore, we conducted a mechanistic study using
an ET receptor antagonist to determine if it could alter the homogeneity of myocardial per-
fusion.
Methods. Included subjects demonstrated a low myocardial perfusion homogeneity index
(HI) compared to normal volunteers. Four serial cardiac positron emission tomography Rb-82
scans were performed 2 weeks apart. Before the middle two scans, subjects were randomized to
receive either darusentan first then placebo or visa versa. Absolute flow and coronary flow
reserve were quantified for each study. Rest flow was adjusted for the pressure-rate product
(PRP).
Results. We screened 37 subjects and randomized 20 who satisfied entry criteria. Rest HI
increased significantly while taking darusentan (0.39 ± 0.10 vs 0.33 ± 0.04 on placebo,
P 5 .030, compared to a normal range of 0.52 ± 0.10) without an increase in the PRP
(6,859 ± 1,503 vs 6,976 ± 1,092, P 5 .79), leading to a higher adjusted flow at rest
(0.69 ± 0.18 cc/minute/g at 7,000 PRP vs 0.59 ± 0.07 with placebo).
Conclusions. Antagonism of the type A ET receptor increases homogeneity of resting
myocardial perfusion. The mechanism appears to be increased absolute rest flow without an
increase in either the PRP or myocardial perfusion during hyperemia. Our translational results
are consistent with one mechanism for the observed heterogeneity of myocardial perfusion in
humans. (J Nucl Cardiol 2013;20:835–44.)
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INTRODUCTION
Myocardial perfusion never appears completely
homogeneous, whether studied on a smaller scale by
microsphere injections1 or on a larger scale by cardiac
positron emission tomography (PET) imaging.2 Hetero-
geneity of myocardial perfusion may occur for a variety of
reasons, including the fundamental fractal vascular struc-
ture of the coronary circulation,1 time-dependent
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capillary ‘‘twinkling’’ as shown by microscopy,3 imaging
technique (for example, count statistics or smoothing
filters), and alterations in coronary vasomotor tone.
Endothelin (ET) plays a key role in this last mechanism,
as its action on type A receptors produces vasoconstric-
tion, serving as one counter mechanism to the effects of
nitric oxide and other endogenous vasodilators.4
Prior animal work from our group has demonstrated
that adenosine can variably reverse perfusion defects
produced by intracoronary infusion of the major vascular
isoform ET-1.5 Such a mechanism may partially account
for our observation that heterogeneity of resting myocar-
dial perfusion, and its improvement after dipyridamole,
predict even mild stress-induced abnormalities.2 Homo-
geneity of myocardial perfusion associates inversely with
classic atherosclerotic risk factors and disease burden.6
Even in young, normal volunteers, occult risk factors
significantly reduce perfusion homogeneity.7
Pharmacologic antagonism of ET in humans has
become possible with a variety of agents. However, their
effect on myocardial perfusion homogeneity has not been
studied. Therefore, we performed cardiac PET before and
after ET blockade with darusentan, an oral antagonist of
the ET type A receptor. Our primary hypothesis was that
darusentan would increase homogeneity of myocardial
perfusion at rest, thereby demonstrating one mechanism
for perfusion heterogeneity. Secondary aims were to
assess the reproducibility of perfusion homogeneity, the
duration of perfusion changes after darusentan adminis-
tration, and if its effects on heterogeneity were mediated




Our study utilized an investigator-initiated, single center,
crossover, placebo-controlled, blinded trial with 1:1 random-
ization. It was performed at the Weatherhead PET Center for
Preventing and Reversing Atherosclerosis of the University of
Texas Medical School at Houston and Memorial Hermann
Hospital. Each subject gave written informed consent
approved by the institutional review board.
Subjects underwent four sequential cardiac PET scans:
baseline, placebo, darusentan, and final. Placebo and darusen-
tan scans occurred second and third, ordered randomly when
study eligibility had been confirmed from the baseline labs and
PET. Drug administration had to occur within 4 weeks of the
baseline PET scan, although all cases started the next day
except 1 subject (3 weeks). Each drug was taken for
14 ± 4 days. Fasting blood work (complete blood count,
comprehensive chemistry panel, serum uric acid, phosphorous,
lactate dehydrogenase, and c-glutamyl transpeptidase) and
urinalysis were performed at most 4 weeks before the baseline
PET and on the day of the final PET. A lipid profile was
performed at baseline.
Randomization of the placebo and darusentan order
allowed for assessment as follows. Subjects whose placebo
scan immediately followed the baseline scan provided infor-
mation on the test-retest reproducibility of myocardial
homogeneity. Subjects whose placebo scan instead followed
the darusentan scan provided information on late washout.
However, all subjects had baseline, darusentan, and washout
studies. Figure 1 depicts the study schematic.
Subject Recruitment and Entry Criteria
Subjects at least 18 years or older were recruited from our
database of prior PET scans. Inclusion criterion was a rest
myocardial heterogeneity at least 2 standard deviations below
originally published normal limits based on an older, rotating
rod PET scanner used at that time.2 During the study, this
criterion was relaxed to at least 1.5 standard deviations to
increase enrollment. See the next section for explicit cutoffs
based on our measure of homogeneity. Exclusion criteria
broadly included uncontrolled or severe comorbidity, inability
to undergo serial PET scans, or contraindication to darusentan.
Specific exclusion criteria were: acute heart failure, sus-
tained and symptomatic hypotension (systolic \90 mm Hg),
uncontrolled hypertension (systolic C170 mm Hg or diastolic
C100 mm Hg), unstable angina, major adverse cardiac event in
prior 6 months (acute myocardial infarction, stroke, transient
ischemic attack, or mechanical revascularization), primary
valvular disease, significant vascular aneurysm, history of renal
or liver failure (elevated serum creatinine, total bilirubin C3 mg/
dL, or serum liver aminotransferase enzyme levels above
twofold the upper limit of normal), active malignancy, life
expectancy under 12 months, uncontrolled diabetes mellitus or
complications of gastroparesis or severe neuropathy, substance
abuse within the last 2 years, active or recent participation
within 1 month of enrollment in another clinical research study,
planned surgical procedure during study, certain herbal food
supplements (L-carnitine, L-arginine, Ginko biloba), prior seri-
ous adverse event attributed to treatment with any ET receptor
agonist, or female subjects who are pregnant or with the potential
for child-bearing, lactating, or treated with hormone therapies.
Potential subjects who had undergone prior PET studies were
contacted by mailings after a preliminary chart review. Those who
were interested signed informed consent and underwent fasting
blood work in advance of the baseline PET scan. If laboratory
testing and medical review did not identify any exclusion criteria,
then the baseline PET scan was performed to determine the resting
perfusion homogeneity. Only subjects who met the baseline
inclusion criterion underwent randomization.
Assignment of subjects to study drug order (placebo then
darusentan or darusentan then placebo) was performed by the
dedicated research pharmacy at our institution using simple 1:1
randomization. An allocation sequence was created using a
random number generator by a statistician not associated with
the study. A printed list of the allocation sequences was
concealed in the research pharmacy and used sequentially for
each randomized subject. Investigators, study subjects, and
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PET center staff performing imaging were blinded to treatment
assignment during the entire trial.
Medications were dispensed in pill bottles containing either
18 tablets of darusentan 100 mg or identical placebo. Each
subject was given one bottle during a treatment period and
returned unused pills on the day of the associated PET scan. Pill
counts performed by the research pharmacy assessed compli-
ance and found no significant deviations. Subjects were
instructed to take one pill each morning including on the day
of a PET scan. Although no study drug intolerance was
identified, the protocol mandated withdrawal of any subject
unable to take the study drug, as dose reduction was not
permitted. During the study, subjects were instructed to continue
all concomitant medications consistently. At each PET scan,
subjects reported on any symptoms noted while taking the study
medication. Symptoms were classified without knowledge of
treatment assignment as headache, congestion, flushing, and
other (including chest tightness, sore throat, edema, myalgia,
nervousness, lightheadedness).
A required sample size of about 40 subjects was estimated
based on a paired t test with a = 0.05, b = 0.80, and a projected
increase from 0.37 to 0.43, which is approximately half a
standard deviation of the normal range for our previously
published2 index of myocardial homogeneity (described next).
No interim analyses or stopping guidelines were considered.
Homogeneity Index (HI)
We previously developed the unitless HI using Markovian
analysis of relative uptake images.2 In brief, the HI quantifies the
intuitive, visual notion of homogeneity. Values near HI = 1
occur when relative uptake is completely uniform. Values near
HI = 0 occur when every uptake pixel differs from its neigh-
bors. To avoid quantifying heterogeneity in areas of scar or
normal myocardium, uptake values below 50% or above 85% of
maximum are set to 50% or 85%, respectively. By design, the HI
favors small uptake differences among adjacent pixels, for
example those present at interfaces among normal myocardium,
scar, and perfusion defects. Four basal slices were not used for HI
analysis due to low counts in the membranous interventricular
septum. Two apical slices were not used for HI analysis due to
potential partial volume errors caused by partial thickness slices
through the LV apex and apical motion.
Our original development of the HI described normal
limits at rest of 0.63 ± 0.13 based on PET images from prior
generation rotating rod PET scanner.2 However, during the
course of this trial, we carried out a more rigorous study of
young, asymptomatic, normal volunteers using a higher
resolution PET scanner with computed tomography (CT)
attenuation correction to determine ‘‘true normal’’ limits of
0.52 ± 0.10 with the same scanner used for the clinical trial.7
Based on a rest cutoff of at least 2 standard deviations below
originally published normal limits,2 we originally required
subjects to have rest HI B 0.63 - (2 9 0.13) = 0.37. To
increase enrollment, the cutoff was relaxed to a rest HI B
0.63 - (1.5 9 0.13) = 0.44 after the first 21 subjects had been
screened and the first 9 had been randomized. However, only 4
(20%) of the 20 randomized subjects had a rest HI [ 0.37. Due
to slight asymmetry of the HI distribution in normal volunteers
imaged by PET-CT, only 2 (10%) of the 20 randomized subjects
had an entry rest HI that would not be considered an outlier using
box-and-whisker plots, as detailed in a subsequent figure.
Figure 1. Study design. If all entry criteria were met after the baseline PET scan, subjects were
randomized to receive either placebo or darusentan first, before crossing over to receive the other
treatment. Four sequential PET scans (#1 to #4) were performed after every 2-week interval. Each
subject had a baseline, darusentan, and washout PET study. Based on the order determined by
randomization, subjects had a PET study to assess either reproducibility or late washout but not
both.
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PET Acquisition and Reconstruction
Protocol
Our imaging protocol has been described previously.7 In
brief, subjects were instructed to fast for 4 hours and abstain
from caffeine, theophylline, and cigarettes for 24 hours.
Cardiac PET was performed using a Discovery ST 16-slice
PET-CT machine (GE Healthcare) in two-dimensional mode
with settings for an in-plane resolution of approximately
6-7 mm full-width at half-maximum.
Rest emission images were obtained over 7 minutes
beginning immediately upon intravenous injection of 1,110 to
1,850 MBq (30 to 50 mCi) of generator-produced Rb-82
(Bracco Diagnostics). The first 2 minutes of emission images
were binned to form arterial input data. The last 5 minutes of
emission images were binned to form myocardial uptake data.
Immediately after completion of the resting scan, dipyridamole
(142 mcg/kg/minute) was infused for 4 minutes. Four minutes
after completion of dipyridamole infusion, the same dose of
radiotracer was given. Stress emission images were acquired
for 7 minutes and binned into arterial and myocardial images
as for the resting scan. Dipyridamole-induced symptoms were
treated with intravenous aminophylline.
CT scans for attenuation correction were acquired before
rest and after stress emission imaging. Protocols for attenua-
tion CT acquisition have been previously reported.8 Fusion
images superimposed PET emission and CT transmission
scans in horizontal, coronal, and sagittal views. Co-registration
was optimized by shifting as needed. PET images were
reconstructed using filtered backprojection with a Butterworth
filter (cutoff 0.55 cycles/cm, rolloff 10 dB/decade, pixel size
3.27 9 3.27 mm). After attenuation correction and reconstruc-
tion, transaxial PET images were exported for analysis on
CARDIAC software (Positron Corporation) to generate true
short- and long-axis views, perpendicular and parallel to the
long-axis of the LV. Circumferential profiles of maximum
radial activity for each true short-axis slice were used to
construct two-dimensional topographic views of the entire LV
in lateral, inferior, septal, and anterior quadrant views.
Assessed for eligibility (n = 37)
Excluded  (n = 17)
♦ Rest homogeneity too high (n = 14)
♦ Renal insufficiency (n = 1)
♦ Dipyridamole contraindications (n = 2)
Analyzed  (n = 13)
♦ Excluded from analysis (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Allocated to darusentan first (n = 13)
♦ Received allocated intervention (n = 13)
♦ Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Allocated to placebo first (n = 7)
♦ Received allocated intervention (n = 7)
♦ Did not receive allocated intervention (n = 0)
Analyzed  (n = 7)
♦ Excluded from analysis (n = 0)
Randomized (n = 20)
Figure 2. Enrollment flow diagram. CONSORT flow diagram of study enrollment, allocation,
follow-up, and analysis.
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In one case, the GE scanner required maintenance and the
subject could not reschedule for logistic reasons. Instead, an
mPower rotating rod PET scanner (Positron Corporation) was
used for imaging. In another case, the GE scanner suffered a
technical malfunction during stress acquisition so that only rest
data was available. For the last subject, the Rb-82 generator
was recalled after the third PET scan. In this case, the final
PET scan took place 29 days later using N-13 ammonia.
Primary and Secondary Endpoints
The primary endpoint was the change in rest myocardial
perfusion homogeneity as quantified by the unitless HI.
Calculation of HI was completely automated by software and
occurred on the day of the PET scan, without subsequent
reprocessing or alteration.
Secondary endpoints were stress HI (computed as for rest
HI but on the stress uptake images), absolute myocardial flow,
and CFR. Originally planned secondary endpoints of relative
uptake perfusion defects and the base-to-apex longitudinal
gradient9 were modified since we developed the technical
ability to measure absolute flow routinely. Peak integrated
activity over an approximate 2 9 2 mm circular area in the left
atrium or thoracic aorta was determined from transaxial
images acquired during the first 2 minutes after each radio-
tracer injection. Integrated myocardial activity during the next
5 minutes was determined from topographical maps of the LV.
For each of 64 radial segments at each of 21 short-axis slices,
integrated arterial input and myocardial uptake were used to
compute absolute myocardial flow using an established
model10 implemented using custom software. The 21 9 64
pixel topographic flow map was smoothed using a 5 9 5 pixel
average to suppress noise introduced by the flow model. CFR
was computed as the stress-to-rest ratio on a pixel-by-pixel
basis. Rest flow was adjusted for baseline pressure-rate product
(PRP) by dividing its measured value by the systolic blood
pressure and heart rate, then multiplying by
7,000 bpm mm Hg (approximately the average resting PRP
at baseline).
Statistical Methods
Statistical analysis was performed using R version 2.13.1
(R Foundation for Statistical Computing, Vienna, Austria).
Continuous variables are expressed as mean ± standard devi-
ation. Frequency variables are expressed as number (percent).
All continuous variables were found to be approximately
normal on inspection of quantile-quantile plots. ANOVA from
a linear mixed effects model with random effects within
subjects assessed changes in primary and secondary endpoints
among baseline, darusentan, and washout PET scans. If this
ANOVA was significant, then a Tukey all-pair comparison was
performed to determine which PET scan(s) were different. A
paired t test compared reproducibility to baseline (for subjects
randomized to placebo first), late image to washout (for
subjects randomized to darusentan first), and baseline and final
laboratory values (for all patients). McNemar’s v2 test com-
pared paired symptoms between placebo and darusentan.
Correlation between continuous variables used the Pearson
coefficient. Bland-Altman analysis used a standard 95%
confidence interval for the limits of agreement. Logistic
regression models were used in a post hoc search for predictors
of darusentan response. All applicable tests were two-tailed
and P \ .05 was considered statistically significant. Box plots
identify outliers as 1.5 times the interquartile range.
Role of the Academic Authors
and Manufacturer
Gilead Sciences supported the trial by supplying the
darusentan and placebo tablets. The corresponding author
obtained an investigator-initiated Investigational New Drug
(IND) permit for darusentan. Gilead paid our academic
medical center an option fee for exclusive use of any
technology stemming from the study. Although Gilead offered
to pay for serum and urine laboratory studies, this option was
not exercised and all laboratory and PET studies were paid for
via internal funding from the Weatherhead PET Center for
Preventing and Reversing Atherosclerosis. The academic
authors had full access to the data, carried out its analysis,
and wrote the manuscript independent of the manufacturer.
However, Gilead did review the manuscript for confidential or
proprietary information but requested no changes. The trial
was registered with clinicaltrials.gov (identifier NCT007
38049).
RESULTS
Subjects underwent enrollment between May 2009
and July 2011. The trial was stopped after 20 enroll-
ments as the manufacturer of darusentan (Gilead
Sciences) halted further development of the drug after
a negative phase 3 trial in resistant hypertension.11
Figure 2 shows the flow diagram for the trial. All
subjects underwent all 4 PET scans and received all
intended treatments, with no losses or exclusions after
randomization. Table 1 lists the baseline and clinical
characteristics of the participants. No adverse events
occurred during the study. Symptoms were reported by 6
(30%) subjects taking placebo (3 headache, 1 flushing, 0
congestion, 3 other) but 16 (80%) subjects taking
darusentan (9 headache, 4 flushing, 4 congestion, 4
other), which differed significantly (P = .009).
Rest HI differed significantly among scans (ANOVA
from linear mixed effects model P value = .030) and was
significantly higher (Tukey P value = .019) while taking
darusentan (0.39 ± 0.10) compared to baseline
(0.33 ± 0.04). Figure 3 shows baseline and darusentan
values for the rest HI, including data on 56 ‘‘true
normals’’ previously published from young, asymptom-
atic volunteers who underwent screening for occult
factors before PET perfusion imaging using the same
scanner as in this darusentan trial.7 Table 2 lists HI,
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hemodynamics, and absolute flow and CFR for the
baseline, darusentan, and washout PET scans. Average
rest flow when adjusted for PRP differed significantly
among scans (ANOVA from linear mixed effects model
P value = .012) and was significantly higher (Tukey
P value = .005) while taking darusentan (0.69 ± 0.18 cc/
minute/g at 7,000 mm Hg bpm) compared to baseline
(0.59 ± 0.07 cc/minute/g at 7,000 mm Hg bpm). Fig-
ure 4 depicts rest images in a normal volunteer and in a
study patient at baseline and while taking darusentan.
A significant correlation existed between rest PRP
and average absolute flow at baseline (r = 0.71, 95%
confidence interval 0.39 to 0.88, P \ .001), as expected
and previously described.6 However, the correlation
between rest PRP and average flow while taking
daursentan was not significant (r = 0.25, 95% confi-
dence interval -0.21 to 0.63, P = .28), suggesting an
uncoupling of PRP from absolute flow as seen with other
vasodilators such as dipyridamole.12
Retest values of rest HI (0.39 ± 0.12) did not differ
significantly from baseline (0.33 ± 0.04, paired t test
P = .26). Bland-Altman analysis of baseline and
reproducibility rest HI showed a mean difference
(reproducibility minus baseline) of ?0.05 (95% confi-
dence interval -0.16 to ?0.26). Late washout values of
rest HI (0.35 ± 0.06) did not decrease further from
washout (0.37 ± 0.08, paired t test P = .66). Bland-
Altman analysis of washout and late washout showed a
mean difference (late minus washout) of -0.01 (95%
confidence interval -0.17 to ?0.15). Rest HI did not
differ significantly between washout and baseline
(paired t test P = .14).
As can be seen in Figure 3, there were 13 (65%)
subjects whose rest HI on darusentan increased by
C10%, 5 (25%) whose rest HI decreased by C10%, and
2 (10%) subjects whose rest HI remained within 10% of
its baseline value. In a post hoc analysis, several
variables (darusentan-induced side effects, age, body
mass index, coronary calcium, hypertension, family
history of early atherosclerosis, prior tobacco, LDL
cholesterol, non-HDL cholesterol, baseline HI value,
baseline blood pressure, and change in systolic blood
pressure, diastolic blood pressure, heart rate, and abso-
lute rest flow from baseline when taking darusentan)
were examined as predictors for rest HI response to
darusentan (binary increase or decrease). Only body
mass index (P = .046) and change in rest flow
(P = .056) had P \ .10, and when studied together
neither remained a significant predictor of rest HI
response to active treatment (adjusted P = .55 and
P = .30, respectively).
Table 1. Baseline characteristics
Number of subjects 20
Age (years) 61 ± 12
Male 19 (95%)
Weight (lbs) 208 ± 26
Body mass index (kg/m2) 29.2 ± 3.6
Hypertension 11 (55%)
Family history of early atherosclerosis 6 (30%)
Diabetes mellitus 0 (0%)
Current or prior tobacco 6 (30%)
Dyslipidemia 20 (100%)
Prior mechanical revascularization* 1 (5%)
Prior myocardial infarction* 1 (5%)






Beta blocker 9 (45%)
Angiotensin blocker 7 (35%)
Total cholesterol (mg/dL) 154 ± 32
HDL (mg/dL) 56 ± 15
LDL (mg/dL) 78 ± 29
Triglycerides (mg/dL) 97 ± 42
Non-HDL cholesterol (mg/dL) 98 ± 34
* Same subject had prior myocardial infarction and mechani-
cal revascularization
Figure 3. Paired homogeneity index. Myocardial perfusion
homogeneity under resting conditions significantly increased
during darusentan treatment compared to baseline (P = .030).
Typical values of resting homogeneity from 56 young, asymp-
tomatic ‘‘true normal’’ volunteers come from our prior work.7
Paired homogeneity index values for all 20 study subjects are
shown in addition to summary box plots.
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Laboratory values did not differ clinically between
the baseline and final PET scans, as shown in Table 3.
No significant correlation existed between rest HI and
body mass index (r2 = 0.05, P = .37) or injected Rb-82
dose (r2 \ 0.01, P = .60).
DISCUSSION
Our translational results support a mechanistic role
for ET in regulating perfusion homogeneity in the
coronary circulation. To our knowledge, we are the first
to modulate ET directly in humans for the purpose of
Table 2. Primary and secondary endpoints
Baseline Darusentan Washout P value
Rest homogeneity (unitless) 0.33 ± 0.04 0.39 ± 0.10* 0.37 ± 0.08 .030
Stress homogeneity (unitless) 0.45 ± 0.08 0.43 ± 0.10 0.43 ± 0.10 .90
Stress-rest homogeneity change (unitless) 0.12 ± 0.09 0.04 ± 0.09 0.06 ± 0.10 .13
Rest systolic blood pressure (mm Hg) 116 ± 12 107 ± 13* 115 ± 14 \.001
Rest diastolic blood pressure (mm Hg) 66 ± 9 60 ± 9* 66 ± 9 \.001
Rest heart rate (bpm) 60 ± 7 64 ± 9* 59 ± 9 .008
Rest pressure-rate product (bpm mm Hg) 6,976 ± 1,092 6,859 ± 1,503 6,817 ± 1,382 .79
Stress systolic blood pressure (mm Hg) 116 ± 11 114 ± 14 117 ± 13 .26
Stress diastolic blood pressure (mm Hg) 64 ± 9 60 ± 8* 65 ± 10 .001
Stress heart rate (bpm) 85 ± 10 87 ± 10 84 ± 11 .32
Rest Rb-82 dose (mCi) 33.0 ± 5.0 32.5 ± 4.6 31.6 ± 6.5 .69
Stress Rb-82 dose (mCi) 32.9 ± 5.0 32.5 ± 4.6 31.7 ± 6.1 .73
Rest average flow (cc/minute/g) 0.58 ± 0.10 0.65 ± 0.13 0.60 ± 0.11 .09
PRP-adjusted rest average flow
(cc/minute/g at 7,000 bpm mm Hg)
0.59 ± 0.07 0.69 ± 0.18* 0.63 ± 0.14 .012
Stress average flow (cc/minute/g) 2.03 ± 0.56 1.97 ± 0.54 1.83 ± 0.55 .30
CFR average (unitless) 3.52 ± 0.80 3.04 ± 0.61 3.11 ± 0.77 .06
* P\ .05 compared to baseline
 P\ .05 compared to darusentan
Figure 4. Example images. Relative uptake maps of the four LV quadrants are shown for a normal
volunteer (top row) from our prior work7 as well as a notable patient at baseline (middle row) and
while taking darusentan (bottom row). The left column shows the raw uptake images while the right
column displays them as analyzed for homogeneity (range truncated to 50%-85%, basal four and
apical two slices removed) along with the homogeneity index value. Whole LV average rest flow
increased from 0.51 cc/minute/g at 7,000 bpm mm Hg at baseline to 0.74 with darusentan.
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studying myocardial perfusion homogeneity. Treatment
with the ET antagonist darusentan significantly
improved resting myocardial perfusion homogeneity.
Improved perfusion homogeneity with darusentan
occurred as average absolute resting flow increased,
especially when accounting for a slightly lower PRP. As
darusentan has been shown to lower blood pressure,13
the observed decrease in these parameters during its
administration is expected and consistent. Normally,
however, PRP and resting flow are directly related.
Therefore, the flat or even inverse relationship between
PRP and resting flow in this data suggests that ET
blockade increases flow by an alternative mechanism,
likely vasodilation.
Note that if ET blockade raised all flows by the
same amount, homogeneity would remain largely
unchanged as it depends on relative differences. Only
altering flow differentially will decrease heterogeneity,
as variation among regions diminishes. Thus, improved
homogeneity with darusentan provides an important
physiologic insight distinct from the obvious and known
vasodilation known to occur with ET antagonism.
Our HI was reproducible under test-retest condi-
tions, which supports its use as an imaging biomarker.
Darusentan did not produce any lasting clinical changes
in rest perfusion homogeneity, blood pressure, or lab-
oratory values beyond the study period. Late washout
values of HI did not differ from those obtained after a
typical washout period, consistent with the known
biologic 12.5 hour half-life of darusentan.
While darusentan improves rest HI, it does not
reach levels seen in young, normal volunteers, suggest-
ing residual factors that produce heterogeneity. This
improved but persistent heterogeneity after darusentan
parallels our prior animal study in which intravenous
adenosine improved but did not normalize myocardial
perfusion defects produced by intracoronary ET-1,
whereas intracoronary adenosine eliminated the residual
perfusion images remaining after intravenous adeno-
sine.5 Higher doses of darusentan (up to 300 mg can be
given daily) may have produced additional increases in
perfusion homogeneity beyond those seen by our
100 mg dose. Additionally, permanent structural
changes in the myocardium may have developed due
to risk factors or manifest heart disease that prevent
normalization of rest HI.
In a minority of subjects, the rest HI on darusentan
either did not increase or even decreased. No predictors
of this response were found in a post hoc analysis. By
analogy, about half of subjects with resistant hyperten-
sion randomized to 100 or 300 mg did not reach blood
pressure goals.13 Also, certain polymorphisms of the
mediating G-protein beta3 subunit may modulate the
vasoconstrictor effect of the ET system,14 and therefore
be important determinants of treatment response to
darusentan. Future work should examine the subgroup of
nonresponders for additional mechanistic insights.
Some potential contributors to perfusion heteroge-
neity arise from the imaging technique: Poisson
counting statistics inherent to radioisotopes, scatter and
attenuation of photons, PET camera noise, selected
reconstruction algorithm, and the applied smoothing
filter. Our demonstrated lack of correlation between the
rest HI and injected dose or body mass index, as well as
good test-retest reproducibility, suggest that these mech-
anisms are not dominant.
Table 3. Laboratory values
Parameter Baseline Final P value
Glucose (mg/dL) 85 ± 14 81 ± 15 .28
Blood urea nitrogen (mg/dL) 18 ± 5 19 ± 6 .14
Creatinine (mg/dL) 1.1 ± 0.2 1.0 ± 0.2 .11
Potassium (mmol/L) 4.6 ± 0.5 4.7 ± 0.5 .45
Total bilirubin (mg/dL) 0.8 ± 0.3 0.7 ± 0.3 .70
AST (U/L) 27 ± 11 26 ± 6 .58
ALT (U/L) 27 ± 10 26 ± 6 .48
Phosphorous (mg/dL) 3.3 ± 0.4 3.5 ± 0.5 .026
Uric acid (mg/dL) 6.6 ± 1.3 6.7 ± 1.5 .69
Lactate dehydrogenase (U/L) 177 ± 53 181 ± 65 .82
c-Glutamyl transpeptidase (U/L) 30 ± 29 30 ± 26 .82
White blood cell count (1,000/lL) 6.5 ± 1.3 6.5 ± 1.6 .98
Hemoglobin (g/dL) 15.0 ± 0.9 14.7 ± 0.8 .034
Platelet count (1,000/lL) 194 ± 39 195 ± 44 .97
Urinalysis (not normal) 1 (5%) 1 (5%) 1.00
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Comparison to Existing Literature
To our knowledge, perfusion heterogeneity in
humans has not been studied previously in the setting
of ET blockade. However, changes in myocardial
perfusion from endothelial dysfunction have been pre-
viously demonstrated in 20 subjects undergoing invasive
coronary physiology evaluation.15 Technetium-99m was
injected into the coronary artery immediately before the
highest dose of the endothelium-dependent vasodilator
acetylcholine. Perfusion defects were noted on imaging
in all 7 subjects with a decrease in coronary blood flow,
compared to 0 subjects whose flow increased. Even
using a more relaxed cutoff of B50% increase in
coronary blood flow, 7 of 11 subjects showed a
perfusion defect compared to 0 of 9 subjects without
endothelial dysfunction. Therefore, our findings of
darusentan-induced changes in myocardial perfusion
have precedent in this model using intracoronary deliv-
ery of acetylcholine.
Invasive coronary physiology was assessed at base-
line and after 6 months in 47 subjects randomized to
daily placebo vs an ET antagonist.16 While baseline flow
increased by 15.3 cc/minute in treated subjects com-
pared to 5.6 cc/minute in those taking placebo, this trend
did not reach statistical significance (P = .25). How-
ever, it mirrors the increase in rest flow seen in our study
while taking darusentan. Long-term ET antagonism
significantly increased endothelium-dependent flow
using acetylcholine (39.7% with blockade compared to
-2.2% with placebo, P \ .001) but not endothelium-
independent CFR using adenosine (-0.3 in both groups,
P = .65). Our study antagonized ET receptors for a
much shorter period of time (2 weeks compared to
6 months) and did not differentiate between endothe-
lium-dependent and endothelium-independent pathways.
A study of 19 community volunteers measured rest
and hyperemic blood flow using cardiac PET before and
during treatment with a selective ET type A antago-
nist.17 ET blockade did not alter the PRP, but increased
resting blood flow from 0.63 to 0.85 cc/minute/g.
However, no change in hyperemic blood flow was noted
during adenosine infusion. These results are similar to
our findings in Table 2 that ET antagonism increases
resting blood flow without increasing the PRP, but
hyperemic flows are not changed.
Prior work has studied the anti-hypertensive effects
of darusentan in refractory hypertension. Our observed
mean decrease in blood pressure of 9/7 mm Hg (sys-
tolic/diastolic) after 2 weeks (P \ .001 compared to
baseline) mirrors observations with the same dose of
darusentan after 14 weeks in 81 patients with refractory
hypertension of 9/5 mm Hg when offset by the placebo
group.13 However, our observed mean increase in
resting heart rate of 4 ± 7 bpm (P = .021) was not
seen in that study. A mild decrease in hemoglobin due to
hemodilution has been reported in other studies of ET
antagonists,13,16 although our final labs were performed
at least 10 days after the last dose of darusentan.
Limitations
For pragmatic reasons we changed the enrollment
HI cutoff value during study recruitment. However,
relaxing the HI cutoff to include more homogeneous
values would, if anything, tend to reduce the observed
effect size compared to including more heterogeneous
values as originally intended. Since 19 of the 20 subjects
were male, our results apply essentially to that gender.
We did not measure serum levels of ET at baseline
or during darusentan treatment. Our motivation for not
doing so was the unclear relation between intracoronary
effects and venous levels of ET. However, variations in
baseline ET might explain the differential response to
darusentan seen in Figure 3. For example, a subject with
low levels of ET might not be expected to respond to its
antagonism, as seen in several subjects with flat HI
values between baseline and active treatment. ET levels
might have provided a mechanistic explanation for
varying treatment response. However, prior work in
volunteers did not find an association between circulat-
ing ET-1 levels and changed rest flow with ET
antagonism.17
CONCLUSION
Homogeneity of resting myocardial perfusion mea-
sured by cardiac PET improved when taking the ET
antagonist darusentan. A potential mechanism for
improved homogeneity is increased and more uniform
rest flow despite a slightly lower PRP. Our translational
results support a mechanistic role for ET in regulating
perfusion homogeneity in the human coronary
circulation.
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